

Product datasheet for TL308391V

OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

WASF2 Human shRNA Lentiviral Particle (Locus ID 10163)

Product data:

Product Type: shRNA Lentiviral Particles

Product Name: WASF2 Human shRNA Lentiviral Particle (Locus ID 10163)

Locus ID:

Synonyms: dJ393P12.2; IMD2; SCAR2; WASF4; WAVE2

Vector: pGFP-C-shLenti (TR30023)

Format: Lentiviral particles

Components: WASF2 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble

control), 0.5 ml each, >10^7 TU/ml.

NM 001201404, NM 006990, NM 006990.1, NM 006990.2, NM 006990.3, NM 006990.4, RefSeq:

NM 001201404.1, NM 001201404.2, BC040943, BC040943.1, BC001524, BC001855, BC012329,

BC032380, BC032724, NM 001201404.3, NM 006990.5

UniProt ID: Q9Y6W5

This gene encodes a member of the Wiskott-Aldrich syndrome protein family. The gene **Summary:**

product is a protein that forms a multiprotein complex that links receptor kinases and actin.

Binding to actin occurs through a C-terminal verprolin homology domain in all family

members. The multiprotein complex serves to tranduce signals that involve changes in cell shape, motility or function. The published map location (PMID:10381382) has been changed based on recent genomic sequence comparisons, which indicate that the expressed gene is located on chromosome 1, and a pseudogene may be located on chromosome X. Two

transcript variants encoding different isoforms have been found for this gene. [provided by

RefSeq, Jan 2011]

These shRNA constructs were designed against multiple splice variants at this gene locus. To shRNA Design:

be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u>.

If you need a special design or shRNA sequence, please utilize our custom shRNA service.





Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).